Eli Lilly and Company launched a new biotech collaboration model to accelerate early-stage drug discovery through external partnerships. This strategic initiative shifts the company’s focus beyond its successful GLP-1 franchise for diabetes and obesity.
The company is actively diversifying its research and development pipeline into autoimmune disease therapies and programmable gene editing treatments. These collaborations aim to establish immunology and genetic medicine as the next primary growth drivers for the firm.
Lilly is leveraging the strong financial outlook provided by its current blockbuster products to fund these expansions into complex therapeutic areas.